Our Chief Medical & Scientific Officer Dr Carol Routledge, discusses some of the key result highlights from our Phase IIa trial of SPL026, what these results could mean for a potential future treatment, and what we'll seek to explore in later-stage clinical trials.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Small Pharma Inc. published this content on 26 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 January 2023 14:22:08 UTC.